Search Results
Your search for all items matches 33996 pages
Showing 501 - 550Making a Difference in Global Oncology
“Making a difference in global oncology means framing positive system changes. To me, Dr. Khalid El Bairi is among the global cancer researchers I know who so far has made the largest achievements. “Since the very first interaction with Khalid, what I have captured is passion for the community he...
Cancer Research and Care Beyond Borders for Global Oncologist Dario Trapani, MD
In this installment of The ASCO Post’s Living a Full Life series, I interviewed Dario Trapani, MD, a medical oncologist at the European Institute of Oncology, Milan and Assistant Professor at the Department of Oncology and Haemato-Oncology of the University of Milan, in Italy. Dr. Trapani is a...
Key Immune Cells for Combating Aggressive Merkel Cell Carcinoma Uncovered
Researchers may have uncovered why some patients with Merkel cell carcinoma do not respond to immune checkpoint blockade therapy, according to a recent study published by Reinstein et al in Cancer Discovery. Background Merkel cell carcinoma—a rare but highly aggressive type of skin cancer—is known...
Fecal Microbiota Transplant May Help Patients With Gastrointestinal Cancers Overcome Immunotherapy Resistance
Fecal microbiota transplants may improve the effectiveness of immunotherapy in patients with gastrointestinal cancers, according to a recent study published by Kim et al in Cell Host & Microbe. Background Although immune checkpoint inhibitors have revolutionized cancer treatment, many patients...
Sara A. Hurvitz, MD, FACP, on New Therapeutic Strategies for HER2-Positive Metastatic Disease Including Brain Metastases
Sara A. Hurvitz, MD, FACP, of Fred Hutch Cancer Center, discusses her presentation on new therapeutic strategies for HER2-positive metastatic disease including brain metastases. Dr. Hurvitz is Senior Vice President and Director, Clinical Research Division, Fred Hutch Cancer Center, and Professor,...
Effect of Posttransplantation Cyclophosphamide-Based GVHD Prophylaxis on Patients With Hematologic Malignancies
In an analysis reported in the Journal of Clinical Oncology, Shaffer et al found that use of post–allogeneic hematopoietic cell transplantation (HCT) cyclophosphamide (PTCy)-based graft-vs-host disease (GVHD) prophylaxis resulted in comparable overall survival and GVHD-free, relapse-free survival...
MRD-Negative ALL: Addition of Blinatumomab to Consolidation Chemotherapy
In the phase III ECOG-ACRIN E1910 trial reported in The New England Journal of Medicine, Mark R. Litzow, MD, and colleagues found that the addition of blinatumomab to consolidation chemotherapy improved overall survival among adult patients with BCR-ABL fusion–negative B-cell precursor acute...
Baseline Bone Pain and Survival in Newly Diagnosed Prostate Cancer
In an analysis from the SWOG-1216 trial reported in JAMA Network Open, Gebrael et al found that the presence of bone pain at diagnosis was associated with poorer progression-free and overall survival in patients with newly diagnosed metastatic hormone-sensitive prostate cancer. Study Details In the ...
Guardant Health’s Shield Blood Test Approved by the FDA as a Primary Screening Option for Colorectal Cancer
On July 29, the U.S. Food and Drug Administration (FDA) approved Guardant Health’s Shield blood test for colorectal cancer screening in adults aged 45 years and older who are at average risk for the disease. It is the first blood test to be approved by the FDA as a primary screening option for...
Is Lower-Dose Radiopharmaceutical Therapy Effective in Advanced Prostate Cancer?
Treatment with de-escalated actinium (Ac)-225–prostate-specific membrane antigen (PSMA)-617 or a combination of lutetium (Lu)-177/Ac-225–PSMA-617 resulted in similar median overall survival and prostate-specific antigen (PSA) response rates and better tolerance among patients with advanced-stage...
Risk of Breast Cancer May Be Lower Within First 10 Years Following Ovarian Cancer Diagnosis
Patients with BRCA1- or BRCA2-mutated ovarian cancer may have a lower risk of developing breast cancer following treatment, according to a recent study published by Evans et al in Genetics in Medicine. Background Previous research has estimated that the risk of developing breast cancer by the age...
Does Bilateral Mastectomy for Unilateral Breast Cancer Impact Mortality?
The results of a contemporary U.S. population–based cohort study published by Giannakeas et al in JAMA Oncology revealed that patients with unilateral breast cancer had an increased risk of breast cancer–related death after developing contralateral disease. Although the findings also showed a...
Patients With Prostate Cancer: Social Factors May Be Tied to Racial Disparities in Cardiovascular Outcomes
Based on the results of a retrospective cohort study published by Demissei et al in JACC: CardioOncology, Black patients with prostate cancer who received systemic androgen-deprivation therapy (ADT) seemed to have a significantly greater likelihood of experiencing adverse cardiovascular disease...
Update on Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial in Patients With Breast Cancer
Guest Editor’s Note: Chemotherapy and its side effects can lead to decreased physical activity and poor diet quality, resulting in unfavorable changes in physical functioning and quality of life. However, adopting healthy behaviors during cancer treatments can be challenging because of physical,...
Triplet as Initial Salvage Treatment for Advanced Germ Cell Tumors: Long-Term Outcomes
In a long-term analysis reported in the Journal of Clinical Oncology, Gleeson et al found that initial salvage treatment for germ cell tumors with paclitaxel, ifosfamide, and cisplatin (TIP) was associated with positive long-term outcomes in both favorable- and unfavorable-risk disease. Study...
New Study Highlights Improvements in Treating Pediatric Patients With Retinoblastoma
The advancement of retinoblastoma treatment over the past 15 years may have resulted in a higher likelihood of vision preservation without compromising survival, according to a recent study presented by Kocharian et al at the Society of NeuroInterventional Surgery (SNIS) Annual Meeting 2024 and...
Cancer Risk From Exposure to Pesticides May Be Comparable to Risk From Smoking, Study Finds
Agricultural pesticides may carry a similar risk as smoking for some types of cancers, according to a recent study published by Gerken et al in Frontiers in Cancer Control and Society. Background In modern agriculture practices, pesticides are essential to ensure high enough crop yields and food...
Localized Hepatocellular Carcinoma
This is Part 3 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of localized hepatocellular...
Advanced Cholangiocarcinoma
This is Part 2 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of advanced...
Advanced Unresectable Hepatocellular Carcinoma
This is Part 1 of Immunotherapy Strategies for Hepatobiliary Cancers, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Rachna T. Shroff, Nilo Azad, and Anthony B. El-Khoueiry discuss the management of advanced unresectable...
Introducing ‘Conexiant’
The publisher and editorial staff of The ASCO Post are happy to share an exciting announcement. While our company was formerly known as Harborside, powered by BroadcastMed, earlier this summer we announced a new name and platform for our business, Conexiant. Importantly, we continue our essential...
Cancer and Fatherhood: A Story of Personal Power in the Face of a Mortal Disease
Iron Dad: A Cancer Survivor’s Story of Discovering Strength, Life, and Love Through Fatherhood by Paul Weigel is an inspiring and deeply moving memoir that transcends the traditional boundaries of parenthood and personal transformation. This story begins with a sense of discontent and a desire for...
Addition of Ibrutinib to Immunochemotherapy and ASCT Improves Survival in Mantle Cell Lymphoma
As reported in The Lancet by Martin Dreyling, MD, PhD, of Ludwig Maximilian University Hospital Munich, and colleagues, results in the European Mantle Cell Lymphoma Network phase III TRIANGLE trial indicate that the addition of ibrutinib to immunochemotherapy and autologous stem cell...
Phase II Study Shows Activity for Novel Targeted Agent in KRAS G12C–Mutated NSCLC
The oral KRAS G12C inhibitor glecirasib has emerged as a therapeutic option for previously treated KRAS G12C–mutated non–small cell lung cancer (NSCLC). It may potentially improve efficacy and tolerability compared with current U.S. Food and Drug Administration–approved agents, according to data...
Updated ASCO Guidance on Cancer-Related Fatigue Expands Patient Options for Interventions
A new update to the ASCO guideline on managing cancer-related fatigue recommends that health care providers urge their patients to exercise, as well as use cognitive-behavioral therapy and mindfulness-based programs to help prevent and treat this prevalent symptom.1 It is estimated that between 30% ...
Amivantamab-vmjw in NSCLC With EGFR Exon 20 Insertion Mutations
On March 1, 2024, amivantamab-vmjw (Rybrevant) was approved for use with carboplatin and pemetrexed for first-line treatment of locally advanced or metastatic non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations, as detected by a U.S. Food and Drug Administration...
Triplet Combination Improves Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Third-Line Setting
The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentuximab vedotin has also shown efficacy and safety in combination with lenalidomide and rituximab in...
ESOPEC Trial: FLOT Protocol Proves Superior to CROSS Regimen in Locally Advanced Esophageal Cancer
The phase III ESOPEC trial, conducted in Germany, compared two regimens for locally advanced esophageal cancer and found an overall survival benefit with the perioperative FLOT protocol over the neoadjuvant chemoradiotherapy CROSS regimen. The results were presented during the Plenary Session of...
Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment: Meeting Highlights
The international meeting in Madrid of the newly formed Alliance for Global Implementation of Lung and Cardiac Early Disease Detection and Treatment (AGILE) was held in May 2024. This diverse forum included health-care professionals, public health leaders, industry representatives, and patient...
Failure to Diagnose and Statutes of Limitations: Lavern’s Law and Its Implications for Oncology
When health-care providers, including oncologists, fail to promptly diagnose a medical condition or communicate their diagnosis to their patients, it can have devastating consequences for those patients. In such cases, patients may seek legal recourse through medical malpractice lawsuits, creating...
Two Phase III Trials Report Benefit With Isatuximab-Based Regimens in Newly Diagnosed Multiple Myeloma
In newly diagnosed, transplant-ineligible patients with multiple myeloma, treatment with the anti-CD38 monoclonal antibody isatuximab plus bortezomib, lenalidomide, and dexamethasone (VRd) led to a 40% reduction in the risk of disease progression or death and “deep and sustained responses,” almost...
RSClin Tool and Risk for Late Distant Recurrence in Breast Cancer
In a study reported in NEJM Evidence, Joseph A. Sparano, MD, and colleagues found that a risk score integrating the 21-gene recurrence score (RS) with clinicopathologic factors—the RSClin tool—performed well in predicting risk of late distant recurrence in patients with breast cancer. Study...
Neoadjuvant Camrelizumab Plus Apatinib in Locally Advanced Colorectal Cancer
In a Chinese phase II study (NEOCAP) reported in The Lancet Oncology, Yu et al found that neoadjuvant camrelizumab plus apatinib produced promising complete response rates in patients with locally advanced microsatellite instability–high or mismatch repair–deficient colorectal cancer. Study ...
Multiple Myeloma: Using Absolute Lymphocyte Count to Predict Outcomes After CAR T-Cell Therapy
A simple blood test that measures lymphocyte counts may predict whether patients with relapsed multiple myeloma are going to respond well to chimeric antigen receptor (CAR) T-cell immunotherapy, according to research published by Saldarriaga et al in Blood Advances. The study found that patients...
Shortening FDA-Mandated CAR T-Cell Therapy Monitoring Periods Could Improve Access to Treatment in Patients With DLBCL
Two hallmark toxicities of chimeric antigen receptor (CAR) T-cell therapy may be rare after 2 weeks following infusion in patients with diffuse large B-cell lymphoma (DLBCL), supporting a shorter, more flexible toxicity monitoring period., according to a recent study published by Ahmed et al in...
Eliminating Racial Disparities in Colorectal Cancer Screening
Eliminating racial disparities in colorectal cancer testing may reduce the rate of colorectal cancer incidence and mortality among Black patients in the United States, according to a recent study published by Alagoz et al in the Journal of the National Cancer Institute. Background Although both the ...
Pancreatic Cancer: Celiac Plexus Radiosurgery for Retroperitoneal Pain Syndrome
In a phase II study reported in The Lancet Oncology, Lawrence et al found that celiac plexus radiosurgery showed promise in the alleviation of retroperitoneal pain syndrome in patients with pancreatic cancer or other tumors involving the celiac axis. Study Details Between January 2018 and December...
Immunotherapy in Unresectable HCC With Child-Pugh Class B Dysfunction
In a retrospective study reported in JAMA Oncology, Fulgenzi et al found evidence that immune checkpoint inhibitor (ICI)-based treatment may improve survival vs best supportive care as first-line therapy in patients with unresectable hepatocellular carcinoma and Child-Pugh class B (CP-B) liver...
Kristin Rojas, MD, FACS, on Improving Sexual Health During Breast Cancer Treatment
Kristin Rojas, MD, FACS, of the University of Miami, shares key points from her discussion on improving sexual health during breast cancer treatment. Dr. Rojas is an Associate Professor of Surgery in the DeWitt Daughtry Family Department of Surgery, Division of Surgery, Miller School of Medicine at ...
Joseph A. Sparano, MD, FACP, on Premenopausal HR-positive Early Breast Cancer: What to Do Outside the OFSET Trial?
Joseph A. Sparano, MD, FACP, of Icahn School of Medicine at Mount Sinai, discusses his presentation on premenopausal patients with hormone receptor–positive early breast cancer. Dr. Sparano is the Ezra M. Greenspan, MD, Professor in Clinical Cancer Therapeutics, Chief of the Division of Hematology...
Does Neighborhood Walkability Impact the Burden of Cardiovascular Risk Factors in Patients With Cancer?
The results of a cross-sectional study reported in JACC: CardioOncology by Nwana et al revealed a significant association between the extent to which a neighborhood facilitates walking and the burden of modifiable cardiovascular risk factors among patients with a history of cancer. “[The findings...
Novel Target Identified for Treating HTLV-1–Associated Diseases
Blocking the tyrosine kinase KDR could lead to cell death caused by the degradation of the TAX viral protein, thereby treating diseases associated with human T-cell leukemia virus type 1 (HTLV-1), according to a recent study published by Mohanty et al in Nature Communications. Background HTLV-1 is...
AACR, ASA, FDA Outline Considerations for Overall Survival Analyses in Clinical Trials
Experts from the American Association for Cancer Research (AACR), American Statistical Association (ASA), and U.S. Food and Drug Administration (FDA) have outlined considerations for clinical trial designs to enhance the collection and analysis of overall survival data in the context of modern-day...
Paolo Tarantino, MD, on the Current and Future Landscape of Antibody-Drug Conjugates
Paolo Tarantino, MD, of Dana-Farber Cancer Institute and Harvard Medical School, shares key points from his discussion on the current and future landscape of antibody-drug conjugates. Dr. Tarantino is an Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute and...
Aditya Bardia, MD, MPH, FASCO, on Novel Therapies Targeting the Estrogen Receptor
Aditya Bardia, MD, MPH, FASCO, of UCLA Health/Jonsson Comprehensive Cancer Center, shares key points from his discussion on novel therapies targeting the estrogen receptor. Dr. Bardia is Professor, Department of Medicine, Division of Hematology/Oncology, and Director of Translational Research...
Tailored Dose-Dense Adjuvant Chemotherapy in High-Risk Early Breast Cancer
As reported in the Journal of Clinical Oncology by Matikas et al, the prespecified end-of-study analysis of the European phase III PANTHER trial showed significant improvements in outcomes with tailored dose-dense vs standard adjuvant chemotherapy in patients with high-risk early breast cancer. As...
Liquid Biopsy May Enable Monitoring of Disease Evolution in Patients With Metastatic Prostate Cancer
DNA/RNA material contained in circulating extracellular vesicles secreted into the blood stream by tumor cells may capture cancer genomics and transcriptomic evolution in patients with metastatic prostate cancer, according to a recent study published by Casanova et al in Cancer Cell. Background...
Panel Issues First Guidelines to Prevent Anal Cancer in Patients With HIV
Researchers have introduced the first screening and treatment recommendations to prevent anal cancer in patients with the human immunodeficiency virus (HIV), according to new guidelines based on the results of a 2022 study published by Palefsky et al in The New England Journal of Medicine....
pMMR/MSS Locally Advanced Rectal Cancer: Immunotherapy-Based Total Neoadjuvant Therapy
In a Chinese phase II trial (TORCH) reported in the Journal of Clinical Oncology, Xia et al found that integration of the PD-1 inhibitor toripalimab into total neoadjuvant therapy was associated with good outcomes in patients with mismatch repair–proficient or microsatellite-stable (pMMR/MSS)...
Early Breast Cancer: Genetic Testing and Communication of Results With Family After Diagnosis
In a U.S. study reported in the Journal of Clinical Oncology, Steven J. Katz, MD, MPH, and colleagues found that many women with early breast cancer and indications for genetic testing do not undergo said testing. Study Details The study involved data from 1,412 women aged 20 to 79 years...
